133 related articles for article (PubMed ID: 11348484)
21. Pharmacokinetics of intrarectal omeprazole in alpacas.
Marmulak T; Stanley S; Kass PH; Wiebe V; McKemie D; Pusterla N
J Vet Pharmacol Ther; 2010 Aug; 33(4):371-5. PubMed ID: 20646199
[TBL] [Abstract][Full Text] [Related]
22. The time course of gastric pH changes induced by omeprazole and ranitidine: a 24-hour dose-response study.
Atanassoff PG; Brull SJ; Weiss BM; Landefeld K; Alon E; Rohling R
Anesth Analg; 1995 May; 80(5):975-9. PubMed ID: 7726442
[TBL] [Abstract][Full Text] [Related]
23. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
[TBL] [Abstract][Full Text] [Related]
24. Variable omeprazole kinetics in healthy Jordanian adults.
Albsoul-Younes A; Tayyem R; Najib N
Biopharm Drug Dispos; 2005 Jul; 26(5):183-8. PubMed ID: 15906422
[TBL] [Abstract][Full Text] [Related]
25. Safety, pharmacokinetics, and pharmacodynamics of S-(-)-pantoprazole sodium injections after single and multiple intravenous doses in healthy Chinese subjects.
Jiao HW; Sun LN; Li YQ; Yu L; Zhang HW; Wang MF; Yu LY; Yuan ZQ; Xie LJ; Chen J; Meng L; Zhang XH; Wang YQ
Eur J Clin Pharmacol; 2018 Mar; 74(3):257-265. PubMed ID: 29167917
[TBL] [Abstract][Full Text] [Related]
26. Twenty-four-hour intragastric acidity: 300 mg ranitidine b.d., 20 mg omeprazole o.m., 40 mg omeprazole o.m. vs. placebo.
Houben GM; Hooi J; Hameeteman W; Stockbrügger RW
Aliment Pharmacol Ther; 1995 Dec; 9(6):649-54. PubMed ID: 8824652
[TBL] [Abstract][Full Text] [Related]
27. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine.
Ley LM; Becker A; Lühmann R; Sander P; Lücker PW
Methods Find Exp Clin Pharmacol; 2005; 27(1):25-9. PubMed ID: 15834456
[TBL] [Abstract][Full Text] [Related]
28. Role of gastric acid secretion in progression of acute gastric erosions induced by ischemia-reperfusion into gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Drozdowicz D; Kwiecieñ S; Pajdo R; Bielanski W; Hahn EG
Eur J Pharmacol; 2000 Jun; 398(1):147-58. PubMed ID: 10856459
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetics and pharmacodynamics of pantoprazole in clinically normal neonatal foals.
Ryan CA; Sanchez LC; Giguère S; Vickroy T
Equine Vet J; 2005 Jul; 37(4):336-41. PubMed ID: 16028623
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group.
Andersson T; Hassall E; Lundborg P; Shepherd R; Radke M; Marcon M; Dalväg A; Martin S; Behrens R; Koletzko S; Becker M; Drouin E; Göthberg G
Am J Gastroenterol; 2000 Nov; 95(11):3101-6. PubMed ID: 11095324
[TBL] [Abstract][Full Text] [Related]
31. Post-prandial ranitidine is superior to post-prandial omeprazole in control of gastric acidity in healthy volunteers.
Khoury RM; Katz PO; Castell DO
Aliment Pharmacol Ther; 1999 Sep; 13(9):1211-4. PubMed ID: 10468703
[TBL] [Abstract][Full Text] [Related]
32. A pharmacokinetic interaction study between omeprazole and the H2-receptor antagonist ranitidine.
Leucuta A; Vlase L; Farcau D; Nanulescu M
Drug Metabol Drug Interact; 2004; 20(4):273-81. PubMed ID: 15663296
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of florfenicol after intravenous and intramuscular dosing in llamas.
Pentecost RL; Niehaus AJ; Werle NA; Lakritz J
Res Vet Sci; 2013 Oct; 95(2):594-9. PubMed ID: 23769151
[TBL] [Abstract][Full Text] [Related]
34. A turnover model of irreversible inhibition of gastric acid secretion by omeprazole in the dog.
Abelö A; Eriksson UG; Karlsson MO; Larsson H; Gabrielsson J
J Pharmacol Exp Ther; 2000 Nov; 295(2):662-9. PubMed ID: 11046103
[TBL] [Abstract][Full Text] [Related]
35. Age-dependent eradication of Helicobacter pylori with dual therapy.
Treiber G; Ammon S; Klotz U
Aliment Pharmacol Ther; 1997 Aug; 11(4):711-8. PubMed ID: 9305480
[TBL] [Abstract][Full Text] [Related]
36. Influence of acid secretory status on absorption of omeprazole from enteric coated granules.
Andersson T; Bergstrand R; Cederberg C
Br J Clin Pharmacol; 1991 Mar; 31(3):275-8. PubMed ID: 2054268
[TBL] [Abstract][Full Text] [Related]
37. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of ranitidine in preterm and term neonates with gastroesophageal reflux.
Asseff IL; Gaucin GB; Olguín HJ; Nájera JA; López AT; Guillé GP; Torres FZ
BMC Pediatr; 2016 Jul; 16():90. PubMed ID: 27412521
[TBL] [Abstract][Full Text] [Related]
39. Effects of anti-acid secretory agents on various types of gastric mucus.
Matsumoto A; Asada S; Okumura Y; Takiuchi H; Hirata I; Ohshiba S
J Clin Gastroenterol; 1992; 14 Suppl 1():S94-7. PubMed ID: 1629582
[TBL] [Abstract][Full Text] [Related]
40. The effect of immobilization stress on the pharmacokinetics of omeprazole in rats.
Watanabe K; Matsuka N; Okazaki M; Hashimoto Y; Araki H; Gomita Y
Acta Med Okayama; 2002 Feb; 56(1):19-23. PubMed ID: 11873940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
